APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antidiabetic Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Antidiabetic Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025193 pages

Choose your research edition.

Industry ResearchAntidiabetic Drug Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Antidiabetic Drug Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Antidiabetic Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antidiabetic Drug Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Antidiabetic Drug Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Antidiabetic Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Antidiabetic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antidiabetic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antidiabetic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Antidiabetic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antidiabetic Drug include Takeda, Eli Lilly, Pfizer, Wockhardt, Tonghua Dongbao, Sanofi-Aventis, Oramed, Novo Nordisk and Halozyme Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antidiabetic Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antidiabetic Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antidiabetic Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antidiabetic Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Antidiabetic Drug Segment by Company

Takeda

Eli Lilly

Pfizer

Wockhardt

Tonghua Dongbao

Sanofi-Aventis

Oramed

Novo Nordisk

Halozyme Therapeutics

Bristol-Myers Squibb

Boehringer Ingelheim

Biocon

Antidiabetic Drug Segment by Type

Dpp-4 Inhibitors

Glp-1 Agonist

Alpha-Glucosidase Inhibitors

Sglt–2

Thiazolodinediones

Meglitinides

Biguanides, Sulphonylureas

Antidiabetic Drug Segment by Application

Type I Diabetes

Type II Diabetes

Antidiabetic Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antidiabetic Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antidiabetic Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antidiabetic Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antidiabetic Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antidiabetic Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Antidiabetic Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Antidiabetic Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Antidiabetic Drug Industry Trends Table 2. Antidiabetic Drug Industry Drivers Table 3. Antidiabetic Drug Industry Opportunities and Challenges Table 4. Antidiabetic Drug Industry Restraints Table 5. Global Antidiabetic Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Antidiabetic Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Antidiabetic Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Antidiabetic Drug Sales Market Share by Manufacturers Table 9. Global Antidiabetic Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Antidiabetic Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Antidiabetic Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Antidiabetic Drug Manufacturers, Product Type & Application Table 13. Global Antidiabetic Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Antidiabetic Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Dpp-4 Inhibitors Table 17. Major Manufacturers of Glp-1 Agonist Table 18. Major Manufacturers of Alpha-Glucosidase Inhibitors Table 19. Major Manufacturers of Sglt–2 Table 20. Major Manufacturers of Thiazolodinediones Table 21. Major Manufacturers of Meglitinides Table 22. Major Manufacturers of Biguanides, Sulphonylureas Table 23. Global Antidiabetic Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Antidiabetic Drug Sales by Type (2021-2026) & (K Units) Table 25. Global Antidiabetic Drug Sales by Type (2027-2032) & (K Units) Table 26. Global Antidiabetic Drug Sales Market Share by Type (2021-2026) Table 27. Global Antidiabetic Drug Sales Market Share by Type (2027-2032) Table 28. Global Antidiabetic Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 29. Global Antidiabetic Drug Revenue by Type (2021-2026) & (K Units) Table 30. Global Antidiabetic Drug Revenue by Type (2027-2032) & (K Units) Table 31. Global Antidiabetic Drug Revenue Market Share by Type (2021-2026) Table 32. Global Antidiabetic Drug Revenue Market Share by Type (2027-2032) Table 33. Major Manufacturers of Type I Diabetes Table 34. Major Manufacturers of Type II Diabetes Table 35. Global Antidiabetic Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Antidiabetic Drug Sales by Application (2021-2026) & (K Units) Table 37. Global Antidiabetic Drug Sales by Application (2027-2032) & (K Units) Table 38. Global Antidiabetic Drug Sales Market Share by Application (2021-2026) Table 39. Global Antidiabetic Drug Sales Market Share by Application (2027-2032) Table 40. Global Antidiabetic Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 41. Global Antidiabetic Drug Revenue by Application (2021-2026) & (K Units) Table 42. Global Antidiabetic Drug Revenue by Application (2027-2032) & (K Units) Table 43. Global Antidiabetic Drug Revenue Market Share by Application (2021-2026) Table 44. Global Antidiabetic Drug Revenue Market Share by Application (2027-2032) Table 45. Global Antidiabetic Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Antidiabetic Drug Sales by Region (2021-2026) & (K Units) Table 47. Global Antidiabetic Drug Sales Market Share by Region (2021-2026) Table 48. Global Antidiabetic Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 49. Global Antidiabetic Drug Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Antidiabetic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. North America Antidiabetic Drug Sales by Country (2021-2026) & (K Units) Table 52. North America Antidiabetic Drug Sales by Country (2027-2032) & (K Units) Table 53. Europe Antidiabetic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Europe Antidiabetic Drug Sales by Country (2021-2026) & (K Units) Table 55. Europe Antidiabetic Drug Sales by Country (2027-2032) & (K Units) Table 56. Asia Pacific Antidiabetic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Asia Pacific Antidiabetic Drug Sales by Country (2021-2026) & (K Units) Table 58. Asia Pacific Antidiabetic Drug Sales by Country (2027-2032) & (K Units) Table 59. South America, Middle East and Africa Antidiabetic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. South America, Middle East and Africa Antidiabetic Drug Sales by Country (2021-2026) & (K Units) Table 61. South America, Middle East and Africa Antidiabetic Drug Sales by Country (2027-2032) & (K Units) Table 62. Global Antidiabetic Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Antidiabetic Drug Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Antidiabetic Drug Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Antidiabetic Drug Revenue Market Share by Region (2021-2026) Table 66. Global Antidiabetic Drug Revenue Market Share by Region (2027-2032) Table 67. Takeda Company Information Table 68. Takeda Business Overview Table 69. Takeda Antidiabetic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Takeda Antidiabetic Drug Product Portfolio Table 71. Takeda Recent Development Table 72. Eli Lilly Company Information Table 73. Eli Lilly Business Overview Table 74. Eli Lilly Antidiabetic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Eli Lilly Antidiabetic Drug Product Portfolio Table 76. Eli Lilly Recent Development Table 77. Pfizer Company Information Table 78. Pfizer Business Overview Table 79. Pfizer Antidiabetic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Pfizer Antidiabetic Drug Product Portfolio Table 81. Pfizer Recent Development Table 82. Wockhardt Company Information Table 83. Wockhardt Business Overview Table 84. Wockhardt Antidiabetic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Wockhardt Antidiabetic Drug Product Portfolio Table 86. Wockhardt Recent Development Table 87. Tonghua Dongbao Company Information Table 88. Tonghua Dongbao Business Overview Table 89. Tonghua Dongbao Antidiabetic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Tonghua Dongbao Antidiabetic Drug Product Portfolio Table 91. Tonghua Dongbao Recent Development Table 92. Sanofi-Aventis Company Information Table 93. Sanofi-Aventis Business Overview Table 94. Sanofi-Aventis Antidiabetic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Sanofi-Aventis Antidiabetic Drug Product Portfolio Table 96. Sanofi-Aventis Recent Development Table 97. Oramed Company Information Table 98. Oramed Business Overview Table 99. Oramed Antidiabetic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Oramed Antidiabetic Drug Product Portfolio Table 101. Oramed Recent Development Table 102. Novo Nordisk Company Information Table 103. Novo Nordisk Business Overview Table 104. Novo Nordisk Antidiabetic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Novo Nordisk Antidiabetic Drug Product Portfolio Table 106. Novo Nordisk Recent Development Table 107. Halozyme Therapeutics Company Information Table 108. Halozyme Therapeutics Business Overview Table 109. Halozyme Therapeutics Antidiabetic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Halozyme Therapeutics Antidiabetic Drug Product Portfolio Table 111. Halozyme Therapeutics Recent Development Table 112. Bristol-Myers Squibb Company Information Table 113. Bristol-Myers Squibb Business Overview Table 114. Bristol-Myers Squibb Antidiabetic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Bristol-Myers Squibb Antidiabetic Drug Product Portfolio Table 116. Bristol-Myers Squibb Recent Development Table 117. Boehringer Ingelheim Company Information Table 118. Boehringer Ingelheim Business Overview Table 119. Boehringer Ingelheim Antidiabetic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Boehringer Ingelheim Antidiabetic Drug Product Portfolio Table 121. Boehringer Ingelheim Recent Development Table 122. Biocon Company Information Table 123. Biocon Business Overview Table 124. Biocon Antidiabetic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Biocon Antidiabetic Drug Product Portfolio Table 126. Biocon Recent Development Table 127. Key Raw Materials Table 128. Raw Materials Key Suppliers Table 129. Antidiabetic Drug Distributors List Table 130. Antidiabetic Drug Customers List Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. Antidiabetic Drug Product Image Figure 2. Global Antidiabetic Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antidiabetic Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Antidiabetic Drug Sales (2021-2032) & (K Units) Figure 5. Global Antidiabetic Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Antidiabetic Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Dpp-4 Inhibitors Image Figure 9. Glp-1 Agonist Image Figure 10. Alpha-Glucosidase Inhibitors Image Figure 11. Sglt–2 Image Figure 12. Thiazolodinediones Image Figure 13. Meglitinides Image Figure 14. Biguanides, Sulphonylureas Image Figure 15. Global Antidiabetic Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Antidiabetic Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 17. Global Antidiabetic Drug Sales Market Share by Type (2021-2032) Figure 18. Global Antidiabetic Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global Antidiabetic Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Antidiabetic Drug Revenue Market Share by Type (2021-2032) Figure 21. Type I Diabetes Image Figure 22. Type II Diabetes Image Figure 23. Global Antidiabetic Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Antidiabetic Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Antidiabetic Drug Sales Market Share by Application (2021-2032) Figure 26. Global Antidiabetic Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Antidiabetic Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Antidiabetic Drug Revenue Market Share by Application (2021-2032) Figure 29. North America Antidiabetic Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 30. North America Antidiabetic Drug Sales Market Share by Country (2021-2032) Figure 31. U.S. Antidiabetic Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Canada Antidiabetic Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Mexico Antidiabetic Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Antidiabetic Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Antidiabetic Drug Sales Market Share by Country (2021-2032) Figure 36. Germany Antidiabetic Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. France Antidiabetic Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. U.K. Antidiabetic Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Italy Antidiabetic Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Netherlands Antidiabetic Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Antidiabetic Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Antidiabetic Drug Sales Market Share by Country (2021-2032) Figure 43. China Antidiabetic Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Japan Antidiabetic Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South Korea Antidiabetic Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Southeast Asia Antidiabetic Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. India Antidiabetic Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Australia Antidiabetic Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Antidiabetic Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Antidiabetic Drug Sales Market Share by Country (2021-2032) Figure 51. Brazil Antidiabetic Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South Africa Antidiabetic Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Saudi Arabia Antidiabetic Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Turkey Antidiabetic Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Argentina Antidiabetic Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. UAE Antidiabetic Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Egypt Antidiabetic Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Chile Antidiabetic Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Global Antidiabetic Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Antidiabetic Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Antidiabetic Drug Revenue (2021-2032) & (US$ Million) Figure 62. North America Antidiabetic Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Antidiabetic Drug Revenue (2021-2032) & (US$ Million) Figure 64. Europe Antidiabetic Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Antidiabetic Drug Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Antidiabetic Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Antidiabetic Drug Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Antidiabetic Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Antidiabetic Drug Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Antidiabetic Drug Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Dpp-4 Inhibitors
  • Glp-1 Agonist
  • Alpha-Glucosidase Inhibitors
  • Sglt–2
  • Thiazolodinediones
  • Meglitinides
  • Biguanides, Sulphonylureas
Applications
  • Type I Diabetes
  • Type II Diabetes
Companies covered
  • Takeda
  • Eli Lilly
  • Pfizer
  • Wockhardt
  • Tonghua Dongbao
  • Sanofi-Aventis
  • Oramed
  • Novo Nordisk
  • Halozyme Therapeutics
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Biocon

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antidiabetic Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antidiabetic Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Antidiabetic Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Antidiabetic Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Antidiabetic Drug Market Dynamics
  1. 2.1 Antidiabetic Drug Industry Trends
  2. 2.2 Antidiabetic Drug Industry Drivers
  3. 2.3 Antidiabetic Drug Industry Opportunities and Challenges
  4. 2.4 Antidiabetic Drug Industry Restraints
3 Antidiabetic Drug Market by Manufacturers
  1. 3.1 Global Antidiabetic Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Antidiabetic Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Antidiabetic Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Antidiabetic Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Antidiabetic Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Antidiabetic Drug Manufacturers, Product Type & Application
  7. 3.7 Global Antidiabetic Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Antidiabetic Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Antidiabetic Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Antidiabetic Drug Tier 1, Tier 2, and Tier 3
4 Antidiabetic Drug Market by Type
  1. 4.1 Antidiabetic Drug Type Introduction
  2. 4.1.1 Dpp-4 Inhibitors
  3. 4.1.2 Glp-1 Agonist
  4. 4.1.3 Alpha-Glucosidase Inhibitors
  5. 4.1.4 Sglt–2
  6. 4.1.5 Thiazolodinediones
  7. 4.1.6 Meglitinides
  8. 4.1.7 Biguanides, Sulphonylureas
  9. 4.2 Global Antidiabetic Drug Sales by Type
  10. 4.2.1 Global Antidiabetic Drug Sales by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Antidiabetic Drug Sales by Type (2021-2032)
  12. 4.2.3 Global Antidiabetic Drug Sales Market Share by Type (2021-2032)
  13. 4.3 Global Antidiabetic Drug Revenue by Type
  14. 4.3.1 Global Antidiabetic Drug Revenue by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Antidiabetic Drug Revenue by Type (2021-2032)
  16. 4.3.3 Global Antidiabetic Drug Revenue Market Share by Type (2021-2032)
5 Antidiabetic Drug Market by Application
  1. 5.1 Antidiabetic Drug Application Introduction
  2. 5.1.1 Type I Diabetes
  3. 5.1.2 Type II Diabetes
  4. 5.2 Global Antidiabetic Drug Sales by Application
  5. 5.2.1 Global Antidiabetic Drug Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Antidiabetic Drug Sales by Application (2021-2032)
  7. 5.2.3 Global Antidiabetic Drug Sales Market Share by Application (2021-2032)
  8. 5.3 Global Antidiabetic Drug Revenue by Application
  9. 5.3.1 Global Antidiabetic Drug Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Antidiabetic Drug Revenue by Application (2021-2032)
  11. 5.3.3 Global Antidiabetic Drug Revenue Market Share by Application (2021-2032)
6 Global Antidiabetic Drug Sales by Region
  1. 6.1 Global Antidiabetic Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antidiabetic Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Antidiabetic Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Antidiabetic Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antidiabetic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Antidiabetic Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Antidiabetic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Antidiabetic Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Antidiabetic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Antidiabetic Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Antidiabetic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Antidiabetic Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Antidiabetic Drug Revenue by Region
  1. 7.1 Global Antidiabetic Drug Revenue by Region
  2. 7.1.1 Global Antidiabetic Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Antidiabetic Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Antidiabetic Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Antidiabetic Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Antidiabetic Drug Revenue (2021-2032)
  8. 7.2.2 North America Antidiabetic Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Antidiabetic Drug Revenue (2021-2032)
  11. 7.3.2 Europe Antidiabetic Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Antidiabetic Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Antidiabetic Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Antidiabetic Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Antidiabetic Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Antidiabetic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Antidiabetic Drug Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Eli Lilly
  8. 8.2.1 Eli Lilly Company Information
  9. 8.2.2 Eli Lilly Business Overview
  10. 8.2.3 Eli Lilly Antidiabetic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly Antidiabetic Drug Product Portfolio
  12. 8.2.5 Eli Lilly Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Antidiabetic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Antidiabetic Drug Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 Wockhardt
  20. 8.4.1 Wockhardt Company Information
  21. 8.4.2 Wockhardt Business Overview
  22. 8.4.3 Wockhardt Antidiabetic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Wockhardt Antidiabetic Drug Product Portfolio
  24. 8.4.5 Wockhardt Recent Developments
  25. 8.5 Tonghua Dongbao
  26. 8.5.1 Tonghua Dongbao Company Information
  27. 8.5.2 Tonghua Dongbao Business Overview
  28. 8.5.3 Tonghua Dongbao Antidiabetic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Tonghua Dongbao Antidiabetic Drug Product Portfolio
  30. 8.5.5 Tonghua Dongbao Recent Developments
  31. 8.6 Sanofi-Aventis
  32. 8.6.1 Sanofi-Aventis Company Information
  33. 8.6.2 Sanofi-Aventis Business Overview
  34. 8.6.3 Sanofi-Aventis Antidiabetic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sanofi-Aventis Antidiabetic Drug Product Portfolio
  36. 8.6.5 Sanofi-Aventis Recent Developments
  37. 8.7 Oramed
  38. 8.7.1 Oramed Company Information
  39. 8.7.2 Oramed Business Overview
  40. 8.7.3 Oramed Antidiabetic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Oramed Antidiabetic Drug Product Portfolio
  42. 8.7.5 Oramed Recent Developments
  43. 8.8 Novo Nordisk
  44. 8.8.1 Novo Nordisk Company Information
  45. 8.8.2 Novo Nordisk Business Overview
  46. 8.8.3 Novo Nordisk Antidiabetic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Novo Nordisk Antidiabetic Drug Product Portfolio
  48. 8.8.5 Novo Nordisk Recent Developments
  49. 8.9 Halozyme Therapeutics
  50. 8.9.1 Halozyme Therapeutics Company Information
  51. 8.9.2 Halozyme Therapeutics Business Overview
  52. 8.9.3 Halozyme Therapeutics Antidiabetic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Halozyme Therapeutics Antidiabetic Drug Product Portfolio
  54. 8.9.5 Halozyme Therapeutics Recent Developments
  55. 8.10 Bristol-Myers Squibb
  56. 8.10.1 Bristol-Myers Squibb Company Information
  57. 8.10.2 Bristol-Myers Squibb Business Overview
  58. 8.10.3 Bristol-Myers Squibb Antidiabetic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bristol-Myers Squibb Antidiabetic Drug Product Portfolio
  60. 8.10.5 Bristol-Myers Squibb Recent Developments
  61. 8.11 Boehringer Ingelheim
  62. 8.11.1 Boehringer Ingelheim Company Information
  63. 8.11.2 Boehringer Ingelheim Business Overview
  64. 8.11.3 Boehringer Ingelheim Antidiabetic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Boehringer Ingelheim Antidiabetic Drug Product Portfolio
  66. 8.11.5 Boehringer Ingelheim Recent Developments
  67. 8.12 Biocon
  68. 8.12.1 Biocon Company Information
  69. 8.12.2 Biocon Business Overview
  70. 8.12.3 Biocon Antidiabetic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Biocon Antidiabetic Drug Product Portfolio
  72. 8.12.5 Biocon Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antidiabetic Drug Value Chain Analysis
  2. 9.1.1 Antidiabetic Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antidiabetic Drug Production Mode & Process
  6. 9.2 Antidiabetic Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antidiabetic Drug Distributors
  9. 9.2.3 Antidiabetic Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst